4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-23-005769
Chief Executive Officer sold 25,000 shares at an average $51.47 ($1,286,798)
- Chief Executive Officer acquired 25,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2023-01-27 | Option exercise | +25,000 | $19.12 | $478,000 | 394,111 | D |
| Kulkarni Samarth Chief Executive Officer | 2023-01-27 | Sale | −1,800 | $50.60 | $91,086 | 392,311 | D |
| Kulkarni Samarth Chief Executive Officer | 2023-01-27 | Sale | −23,200 | $51.54 | $1,195,712 | 369,111 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2023-01-27 | Option exercise · Stock Option (Right to Buy) | −25,000 | 179,582 | D | ||
| Open-market sales · 25,000 sh · avg $51.47 · $1,286,798 | |||||||
Loading xslF345X03/doc4.xml…